Earnings Call · Q4 FY2021·2022-03-10

Q4 21EPS -33.33%·Rev n/aQ3 21EPS +6.72%·Rev n/aQ2 21EPS -57.86%·Rev n/aQ1 21EPS -100.00%*·Rev n/a⚠ consensus missing

Viridian Therapeutics, Inc.\DE VRDN

John Jordan — Chief Executive Officer

Jonathan Violin — Chief Executive Officer

Kristian Humer — Chief Financial Officer and Chief Business Officer

+5.5%1d on move date+6.7% vs SPY3d+4.6%5d+5.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VRDN calls or request research access.

More VRDN calls Browse calls Request research access